-
-
-
-
-
-
-
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
-
-
-
-
-
-
-
Sosei Heptares Operational Highlights and Consolidated Results for Nine Months ended 30 September 2021
-
-
-
-
-
-
-
Sosei Heptares Operational Highlights and Consolidated Results for the First Half 2020
-
-
-
-
-
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

